Efficacy and safety of azithromycin in the treatment of moderate to severe bronchiolitis
-
摘要: 目的 探讨阿奇霉素治疗中重度毛细支气管炎患儿的疗效及安全性。 方法 收集2017年8月—2018年4月于蚌埠医学院第一附属医院儿科住院治疗的中重度毛细支气管炎患儿75例,采用随机数字表法将其分为阿奇霉素干预组(37例)和常规治疗组(38例)。常规治疗组给予抗病毒、布地奈德联合沙丁胺醇雾化吸入等常规治疗。阿奇霉素干预组在对照组常规治疗的基础上加用阿奇霉素干混悬剂[10 mg/(kg·d)]口服治疗3 d。对2组患儿临床危重度(CS)评分进行比较;并比较2组患儿咳嗽、喘息、三凹征及肺部啰音消失时间、2组患儿住院时间以及中性粒细胞减少、血小板减少、胃肠道症状、心率失常、肝损害不良事件的发生情况。 结果 2组组内治疗前后CS评分比较差异有统计学意义(F=139.111、158.341,均P<0.001);常规治疗组CS评分显著高于阿奇霉素干预组(F=7.008,P=0.010);阿奇霉素干预组患儿咳嗽、喘息、三凹征、肺部啰音消失时间及住院时间均短于常规治疗组,差异有统计学意义(均P<0.05);2组患儿肝损害、胃肠道症状、心率失常不良事件的发生情况比较,差异无统计学意义(均P>0.05)。 结论 阿奇霉素治疗毛细支气管炎是安全的,并可显著改善毛细支气管炎患儿的症状、体征,缩短病程,可在临床推广应用。Abstract: Objective To investigate the efficacy and safety of azithromycin in children with moderate to severe bronchiolitis. Methods A total of 75 children with moderate to severe bronchiolitis hospitalized in the department of pediatrics of the First Affiliated Hospital of Bengbu Medical College from August 2017 to April 2018 were selected and divided into azithromycin intervention group (37 cases) and routine treatment group (38 cases) by random number table method. The routine treatment group was given routine treatment such as antiviral, budesonide combined with salbutamol atomization inhalation. The azithromycin intervention group was treated with azithromycin dry suspension [10 mg/ (kg·d)] for 3 days on the basis of the routine treatment in control group. The clinical criticality (CS) scores of the two groups were compared. The time of cough, wheezing, three concave sign and rale disappearance in lung, hospitalization time, and the adverse events such as neutropenia, thrombocytopenia, gastrointestinal symptoms, arrhythmia of heart rate and liver damage, were compared between the two groups. Results There were significant differences in CS scores before and after treatment between two groups (F=139.111, 158.341, all P<0.001). The CS score of the routine treatment group was significantly higher than that of the azithromycin intervention group (F=7.008, P=0.010). The cough, wheezing, triple concave sign, lung rale disappearance time and hospitalization time in the azithromycin intervention group were shorter than those in the routine treatment group (all P<0.05). There was no significant difference between the two groups in the occurrence of adverse events, such as liver damage, gastrointestinal symptoms and arrhythmia (all P>0.05). Conclusion Azithromycin is safe for the treatment of bronchiolitis, which significantly improve the symptoms and signs of children with bronchiolitis, shorten the course of disease, and can be applied in clinic.
-
Key words:
- Bronchiolitis /
- Azithromycin /
- Clinical symptom score
点击查看大图
计量
- 文章访问数: 202
- HTML全文浏览量: 24
- PDF下载量: 0
- 被引次数: 0